Randomized control trial of blant-TAE with embosphere or gelpart for large hepatocellular carcinoma

Randomized control trial of blant-TAE with embosphere or gelpart for large hepatocellular carcinoma - BEWELL study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026838

Enrollment

Registered

2017-05-01

Start date

2017-03-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

embosphere gelpart

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Histologically or clinically diagnosed as hepatocellular carcinoma. 2)Tumor size 5cm or larger. 3)No candidate for surgery or ablation therapy. 4)Five or fewer tumors (>2 cm) 5)Child-Pugh classification A or B. 6)Expected survival time over 3 months. 7)Without dysfunction of bone marrow, heart, lung, kidney.

Exclusion criteria

Exclusion criteria: 1)Invasion of main portal vein (Vp3, Vp4) or inferior vena cava. 2)Hepatic encephalopathy or refractory ascites. 3)Allergy to contrast media. 4)Pregnant, possibly pregnant. 5)Patients who are not suitable to be participated due to medical reason evaluated by primary physician

Design outcomes

Primary

Measure	Time frame
Response rate(4 weeks)	—

Secondary

Measure	Time frame
Tumor contraction rate. Time to progression. Safety. Overall survival rate.	—

Countries

Japan

Contacts

Public ContactYoshiaki Tanaka

Kitasato University Departments of Gastroenterology

tanakay@kitasato-u.ac.jp042-778-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026